CASI PHARMACEUTICALS, INC. Research and Development Expense
CASI PHARMACEUTICALS, INC. (CASIF) reported Research and Development Expense of $6.31 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-05-15
| Period end | Research and Development Expense 12 month |
|---|---|
| 2025-12-31 | $6.31M 20-F · filed 2026-05-15 |
| 2024-12-31 | $8.92M 20-F · filed 2026-05-15 |
| 2023-12-31 | $9.86M 20-F · filed 2026-05-15 |
| 2022-12-31 | $16.00M 20-F · filed 2025-03-31 |